Clinical Trial Update: A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating amivantamab in participants with advanced or metastatic solid tumors, including epidermal growth factor receptor-mutate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Carcinoma, Non-small-Cell Lung | Phase 2 | Status: RECRUITING